ID 63. Impact of Packed Red Blood Cell Transfusions on Cerebral and Somatic Tissue Oxygenation in Premature infants with and without a Patent Ductus Arteriosus

Doctor Aisling Smith¹, Doctor Sean Armstrong¹, Professor Eugene Dempsey², Professor Afif EL-Khuffash¹

¹The Rotunda Hospital, Dublin, Ireland, ²Cork University Maternity Hospital, Cork, Ireland

Background: Packed red blood cell (PRBC) transfusions treat anaemia and support adequate cellular metabolism. The impact of PRBC transfusions on left ventricular (LV) afterload and pulmonary vascular resistance (PVR), cerebral and somatic regional tissue oxygenation (rSO2) in the context of a patent ductus arteriosus (PDA) warrants further investigation.

Methods: Infants <32 weeks gestation who received a PRBC transfusion beyond the first 10 days of life were included. Each infant underwent a 24 hour assessment of cerebral and somatic rSO2 and fractional tissue oxygen extraction (FTOE), commencing at the start of the transfusion. Echocardiography was carried out at: baseline, 18 hours and 24 hours post transfusion, to measure PVR, LV end systolic wall stress (ESWS) in addition to LV and Right ventricular (RV) systolic strain. The impact of the presence of a PDA on cerebral and somatic rSO2/FTOE was assessed.

Results: Thirty infants with a median [IQR] gestation and birthweight of 26.3 [24.8 – 28.0] weeks and 855 [659 – 1103] grams were included. Baseline haemoglobin was 10.0 [9.3 – 10.5] g/dL. There was an increase in pulmonary artery acceleration time (48 ± 13 to 57 ± 16 ms, p<0.01) from baseline to 24 hours post transfusion. LV ESWS did not change (378 ± 149 to 361 ± 132 dynes/cm², p=0.67). There was no change in LV or RV strain over the study period (p>0.05). Ten infants had a PDA (median diameter 2.1 [1.8 – 2.7] mm). Cerebral rSO2 increased in a similar manner in infants with and without a PDA following PRBC transfusion with a corresponding fall in cerebral FTOE (Figure). Although somatic rSO2 increased during the study period in the overall group, the rSO2 values were significantly lower in those with an open PDA at baseline and following transfusion compared to those with a closed PDA. There was a significant decrease in somatic FTOE following transfusion in the closed PDA group only (Figure).

Conclusion: PRBC transfusion results in a fall in PVR without significant change in myocardial function or LV afterload. Cerebral oxygenation improved following transfusion regardless of PDA status. Somatic oxygenation improved to a greater extent in babies with a closed PDA.
Cerebral and somatic rSO2 and FTOE
Cerebral and somatic rSO2 and FTOE
None Declared
ID 232. THROMBIN GENERATION IN THE PREMATURE INFANT; THE EFFECT OF PLATELETS

**Dr. Claire Murphy**1,2, Dr. Elaine Neary4,5, Dr. Barry Kevane3,6, Dr. Daniel O’Reilly2, Mr. John O’Loughlin7, Prof. Afif EL-Khuffash1,2, Prof. Patricia Maguire3, Prof. Fionnuala NiAinle3,6,8, Prof. Naomi McCallion1,2

1Department of Paediatrics, Royal College Of Surgeons In Ireland, Dublin, Ireland, 2Department of Neonatology, Rotunda Hospital, Dublin, Ireland, 3Conway-SPHERE Research group, Conway Institute, University College Dublin, Dublin, Ireland, 4Department of Neonatology, Liverpool Women’s Hospital, Liverpool, United Kingdom, 5Department of Health and Life Sciences, University of Liverpool, Liverpool, United Kingdom, 6Department of Haematology, Mater Misericordiae University Hospital, Dublin, Ireland, 7Department of Pathology, Rotunda Hospital, Dublin, Ireland, 8School of Medicine, University College Dublin, Dublin, Ireland

**BACKGROUND**

Premature infants are at risk of haemorrhage, particularly intraventricular haemorrhage, and have reduced coagulation factor levels and hypo-reactive platelets in vitro. In spite of these recognized changes, plasma thrombin generation (characterized by Calibrated Automated Thrombography (CAT)) in preterm infants, is similar or enhanced compared with term infants. The aim of this study, the EVENT study, is to characterize platelet-dependent thrombin generation in premature infants.

**METHODS**

This was a prospective observational study, performed in platelet rich (PRP) and platelet poor (PPP) plasma obtained from umbilical cord blood, collected in sodium citrate (PRP: 200 x 10 mins; PPP: 3000 RPM x 6 mins x 2). Premature infants (24 - 31 weeks) and healthy term controls were recruited. Using a CAT assay, thrombin generation was stimulated by tissue factor only (final concentration 1pM), rendering the assay dependent upon the phospholipid content of plasma. Hospital ethical approval and parental consent was obtained.

**RESULTS**

In a preliminary analysis of the first thirty patients (n=13 preterm, n=17 term), CAT parameters in umbilical cord blood PRP were similar between preterm and term infants (Table 1). However, the time to peak thrombin was significantly shorter in premature infants, a marker of hypercoagulability.

In a subset of infants (n=7 term, n=6 preterm), thrombin generation was assessed in paired PPP and PRP using 1pM TF only, to evaluate the impact of platelets on neonatal thrombin generation. No difference was observed in any CAT parameters, suggesting that neonatal PPP phospholipid content (potentially from circulating extracellular vesicles) is sufficient to support thrombin generation in the absence of exogenous phospholipid.

**CONCLUSION**

These preliminary data suggest that thrombin generation in PRP is similar or enhanced in preterm compared with term infants. Moreover, neonatal plasma phospholipid appears to support thrombin generation in the absence of exogenous phospholipid. This ongoing large prospective study aims to further characterize the platelet-dependency of neonatal thrombin generation in both umbilical cord blood and neonatal peripheral blood.
Table 1: CAT parameters in PRP in umbilical cord blood. Median values displayed (interquartile range).

<table>
<thead>
<tr>
<th>Parameters</th>
<th>N=13</th>
<th>N=17</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gestational age (weeks) IQR</td>
<td>29.6 (28 – 29.9)</td>
<td>39.3 (38.9 – 39.7)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Birth weight (g)</td>
<td>1375 (1070 – 1450)</td>
<td>3830 (3400 – 4060)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Whole blood platelet count (x10^9/L) IQR</td>
<td>247 (220 – 284)</td>
<td>255 (223 – 277)</td>
<td>0.86</td>
</tr>
<tr>
<td>PRP platelet count (x10^9/L) IQR</td>
<td>100 (61 – 142)</td>
<td>107 (93 – 179)</td>
<td>0.13</td>
</tr>
<tr>
<td>CAT parameters</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lag Time (mins) IQR</td>
<td>3.83 (3.26 - 4.33)</td>
<td>4.28 (3.85 - 4.5)</td>
<td>0.13</td>
</tr>
<tr>
<td>ETP (nM.min) IQR</td>
<td>1002.94 (831.51 - 1182.74)</td>
<td>969.94 (898.28 - 1000.1)</td>
<td>0.34</td>
</tr>
<tr>
<td>Peak Thrombin (nM) IQR</td>
<td>80.81 (62.96 - 121.87)</td>
<td>76.47 (56.63 - 85.73)</td>
<td>0.22</td>
</tr>
<tr>
<td>Time to Peak (mins) IQR</td>
<td>9.25 (8.33 - 10.17)</td>
<td>10.45 (9.33 - 11.74)</td>
<td>0.046*</td>
</tr>
</tbody>
</table>

Prof. Fionnuala NíAinle has received research funding (paid to the University) from Bayer and Sanofi (unrelated to this study).
ID 579. SURVEY OF TRANSFUSION PRACTICES IN EUROPEAN PRETERM INFANTS (STEP SURVEY)

Dr Alexandra Scrivens1, Dr Nora-Johanna Reibel2, Dr Lisanne Heeger3, Professor Simon Stanworth5, Professor Enrico Lopriore4, Professor Helen New4, Dr Christof Dame1, Dr Emöke Deschmann7, Professor Karin Fijnvandraat6, Dr Anskes van der Bom6, Dr Marta Aguar Carrascosa8, Dr Kristin Braekke9, Dr Francesco Cardona10, Dr Filip Cools11, Dr Ryan Farrugia12, Dr Stefano Ghirardello13, Dr Jana Lozar Krivec14, Dr Katarina Matasova15, Dr Tobias Mühlbacher16, Dr Ulla Sankilampi17, Dr Henrique Soares18, Professor Miklós Szabó19, Professor Tomasz Szczapa20, Professor Gabriela Zaharie21, Professor Charles Christof Roehr22, Dr Suzanne Fustolo-Gunnink4
1Oxford University Hospitals, Oxford, United Kingdom, 2Charité University Hospital, Berlin, Germany, 3Sanquin Blood Supply Foundation, Amsterdam, The Netherlands, 4Leiden University Medical Center, Leiden, The Netherlands, 5NHS Blood and Transplant, London, UK, 6Amsterdam UMC, Amsterdam, The Netherlands, 7Karolinska Institute, Solna, Sweden, 8La Fe University Hospital, Valencia, Spain, 9Oslo University Hospital, Ullevål, Oslo, Norway, 10Medical University Vienna, Austria, 11Universitair Ziekenhuis Brussel, Brussels, Belgium, 12Mater Dei Hospital, Malta, 13Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy, 14University Medical Center Ljubljana, Ljubljana, Slovenia, 15Martin University Hospital, Martin, Slovakia, 16University Hospital Zurich, Zurich, Switzerland, 17Kuopio University Hospital, Kuopio, Finland, 18Centro Hospitalar Universitário de São João, Porto, Portugal, 19Semmelweis University, Budapest, Hungary, 20Poznan University of Medical Sciences, Poznan, Poland, 21University of Medicine and Pharmacy Iuliu Hatieganu Cluj, Cluj Napoca, Romania, 22University of Oxford, Oxford, UK

BACKGROUND

Transfusions of red blood cells (RBC), platelets and plasma are often provided to infants born at less than 32 weeks’ gestation. Although several randomized controlled trials on thresholds for RBC and platelet transfusions have recently been published, international consensus guidelines are lacking. As an initiative of the newly formed Neonatal Transfusion Network (NTN), a survey on current transfusion practice was performed across NICUs in 18 European countries.

METHODS

The survey was distributed amongst neonatal units in 18 European countries between October and December 2020, asking specifically about transfusion thresholds, indications, volumes and rates of transfusion for infants born <32 weeks.

RESULTS

The analysis included responses from 343 NICUs across 18 European countries: Austria, Belgium, Finland, Germany, Hungary, Italy, Malta, The Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland and the United Kingdom. The median response rate per country was 57% (range: 21 - 100%).

RBC transfusion thresholds varied (figure 1), and were usually higher in younger infants and those requiring a higher level of respiratory support.

In 53% of NICUs, clinically stable neonates without signs of bleeding were reported to receive platelet transfusion at a platelet threshold higher than 25x10^9/L, despite the results of the PLANET2 study. Platelet transfusion thresholds showed substantial variation between NICUs, trending towards higher thresholds in infants undergoing procedures, surgery or active bleeding.

Plasma is routinely given to infants with coagulopathy and active bleeding in 93% of NICUs, coagulopathy alone in 30%, active bleeding alone in 45%, and volume replacement in 26% of NICUs. Plasma is administered for sepsis in 26% of NICUs.
The median volumes of RBC, platelets and plasma given per transfusion were 15ml/kg. The rates of transfusion however varied significantly with interquartile ranges: RBC: 3.75-5ml/kg/hr, platelets: 7.5-20ml/kg/hr, plasma 5-15ml/kg/hr.

CONCLUSION
Blood component transfusion thresholds, indications, volumes and rates vary considerably across European NICUs. There is a rationale for assimilation of the existing evidence into guidelines. These findings may motivate quality improvement projects to bridge the evidence-practice gap and for further investigation to establish optimal rates and volumes for blood component transfusion in infants born preterm. Our survey provides a starting point for this work.

Figure 1: [Low flow = 0-2l/min nasal cannula oxygen; NIV <30 = non-invasive ventilation with FiO2 < 30%; NIV >30 = non-invasive ventilation with FiO2 > 30%]

None declared
ID 300. DOES THE CURRENT GUIDANCE ABOUT MANAGEMENT OF THROMBOCYTOPENIA DELIVER THE DESIRED RESULTS?

**Doctor Rebeka Conry**, Doctor Anupam Gupta, Doctor Arindam Mukherjee

1St Mary’s Hospital, Manchester, United Kingdom

**BACKGROUND**

Platelet transfusions are a frequent procedure for premature neonates. There are a number of reasons why prematurity is a risk factor for requiring platelet transfusion; necrotising enterocolitis (NEC) and sepsis to name a few. While recent trials have addressed the question of ideal cut off for platelet transfusion, optimal dosing of the platelets remains contentious.

**METHODS**

This quality improvement project is a retrospective analysis of all neonates born or transferred into a tertiary neonatal intensive care unit (NICU). Very premature infants of less than 32 weeks’ gestation who received platelet transfusion were selected (n=106) over a 12-month period in 2019. The primary outcome of increment in platelet counts was then analysed in relation to the dosing, indications and relationship to NEC or sepsis.

**RESULTS**

The study collected data for transfusions from January to December 2019. During the study period, we identified 106 neonates. 11 of these neonates received a platelet transfusion. Our mean birth gestation of neonates was 25 weeks, gestational age at transfusion was 32 weeks and a mean weight of 1.27kg. 50 platelet transfusions were given to 11 eligible infants. Mean birth gestation and corrected gestation was 25 and 32 weeks respectively.

74% of the transfusions followed the guideline and 94% received 15ml/kg of platelets. The data revealed that 3/50 (6%) transfusions resulted in platelet count of >150 x10⁹. On further subgroup analysis, inflammatory markers (CRP) demonstrated a low correlation coefficient of -0.09 (p=0.56). Infants managed for NEC had a mean rise of 77.8 x 10⁹/L in comparison to 33.9 x 10⁹/L for infants without NEC. There was a trend towards statistical significance (p= 0.05).

**CONCLUSION**

Our study showed that the current practice of 15ml/kg led to an inadequate rise in a significant proportion of babies. It also showed that while there is good compliance to national recommendation for platelet volume, about a quarter of babies are still being transfused inappropriately. It also did not reveal any correlation with sepsis while suggesting that infants without NEC appeared to have a suboptimal response. This did not reach statistical significance and hence warrants a larger study.

None declared